Wall Street brokerages forecast that Pulse Biosciences Inc (NASDAQ:PLSE) will post earnings per share of ($0.61) for the current quarter, according to Zacks. Zero analysts have made estimates for Pulse Biosciences’ earnings. Pulse Biosciences posted earnings per share of ($0.51) in the same quarter last year, which suggests a negative year-over-year growth rate of 19.6%. The company is scheduled to announce its next quarterly earnings results on Thursday, February 6th.
On average, analysts expect that Pulse Biosciences will report full-year earnings of ($2.21) per share for the current fiscal year. For the next financial year, analysts expect that the firm will report earnings of ($1.80) per share. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Pulse Biosciences.
Pulse Biosciences (NASDAQ:PLSE) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.57) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.04.
PLSE has been the subject of several recent analyst reports. Zacks Investment Research raised Pulse Biosciences from a “hold” rating to a “buy” rating and set a $16.00 price objective for the company in a report on Thursday. ValuEngine raised Pulse Biosciences from a “sell” rating to a “hold” rating in a report on Wednesday, October 30th. Finally, BidaskClub downgraded Pulse Biosciences from a “hold” rating to a “sell” rating in a report on Thursday, October 31st.
A number of institutional investors have recently made changes to their positions in PLSE. BlackRock Inc. lifted its holdings in Pulse Biosciences by 17.2% during the 2nd quarter. BlackRock Inc. now owns 734,566 shares of the company’s stock valued at $9,695,000 after purchasing an additional 108,059 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Pulse Biosciences by 5.2% during the 2nd quarter. Vanguard Group Inc. now owns 463,194 shares of the company’s stock valued at $6,114,000 after purchasing an additional 22,800 shares during the last quarter. Westside Investment Management Inc. acquired a new stake in Pulse Biosciences during the 2nd quarter valued at $5,074,000. Griffin Asset Management Inc. lifted its holdings in Pulse Biosciences by 11.6% during the 2nd quarter. Griffin Asset Management Inc. now owns 57,315 shares of the company’s stock valued at $757,000 after purchasing an additional 5,955 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC acquired a new stake in Pulse Biosciences during the 2nd quarter valued at $55,000. 9.83% of the stock is owned by institutional investors and hedge funds.
NASDAQ PLSE opened at $14.09 on Friday. The company has a market cap of $295.82 million, a PE ratio of -6.40 and a beta of 1.84. The company has a current ratio of 8.88, a quick ratio of 8.88 and a debt-to-equity ratio of 0.09. Pulse Biosciences has a 12 month low of $9.52 and a 12 month high of $19.77. The stock has a 50 day moving average of $14.69 and a 200-day moving average of $13.19.
Pulse Biosciences Company Profile
Pulse Biosciences, Inc operates as a clinical stage medical therapy company. It engages in the research and development, and commercialization of CellFX system that provides a precise and non-thermal cellular treatment technology delivering nanosecond duration energy pulses that impact cells in treated tissue while sparing surrounding non-cellular tissue primarily for dermatology applications.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.